Large Cell Neuroendocrine Carcinoma: A Comprehensive Research Report

1. Disease Information

Overview. Large cell neuroendocrine carcinoma (LCNEC) is a high-grade, poorly differentiated neuroendocrine carcinoma composed of large malignant epithelial cells that display neuroendocrine morphology (organoid nesting, palisading, rosette-like structures) together with high mitotic activity (>10 mitoses/2mm²) and often geographic necrosis (PathologyOutlines; Wikipedia). It was historically classified as a variant of large-cell lung carcinoma but is now recognized in the 2021 WHO Classification of Thoracic Tumours as one of two neuroendocrine carcinomas of the lung (alongside small cell lung carcinoma, SCLC), distinct from the low/intermediate-grade neuroendocrine tumors (typical and atypical carcinoid) (PathologyOutlines). Although the pulmonary form is the prototype and best studied, LCNEC also arises as a primary tumor in extrapulmonary sites — GI tract, pancreas, cervix, uterus, ovary, bladder, prostate, breast, larynx/pharynx, paranasal sinus, and thymus (Frontiers, Management of LCNEC, PMID:34513663; PMC10743506).

Key identifiers. - MONDO: MONDO:0018316-class term(s) for "large cell neuroendocrine carcinoma" (cross-referenced through the Monarch Initiative/NORD MONDO disease pages); the entity has organ-specific children (lung, breast, cervical, thymic, etc.) (NORD/MONDO). - ICD-O-3 morphology code: 8013/3 (Large cell neuroendocrine carcinoma). - ICD-11: 2C25.4 (malignant neuroendocrine neoplasms of bronchus or lung) with extension code XH0NL5 for large cell neuroendocrine carcinoma (AHA Coding Clinic). - ICD-10-CM: indexed under C34.- (malignant neoplasm of bronchus and lung) for the pulmonary primary, with topography-specific codes for extrapulmonary primaries. - MeSH: falls under "Carcinoma, Neuroendocrine" (D018277) and "Carcinoma, Large Cell" (D018281). - No dedicated OMIM or Orphanet entry exists specifically for sporadic LCNEC, as it is not a classical monogenic disorder; Orphanet does catalog rare neuroendocrine tumor syndromes (e.g., MEN1) that can predispose to related neuroendocrine neoplasia.

Synonyms/alternative names: Pulmonary large-cell neuroendocrine carcinoma (LCNEC, PLCNC); large cell/neuroendocrine carcinoma; high-grade neuroendocrine carcinoma (large cell type); "non-small cell neuroendocrine carcinoma" (older, discouraged terminology).

Data provenance. The evidence base combines: (1) aggregated population-level registry data (SEER, national cancer registries), (2) large retrospective single- and multi-institutional clinicopathologic cohorts, (3) integrative genomic/transcriptomic sequencing cohorts (tumor-level, not EHR-derived), and (4) a growing number of prospective clinical trials (phase II basket and single-arm trials). There is comparatively little large-scale EHR-based real-world evidence relative to more common cancers, reflecting LCNEC's rarity (~1–3% of all lung cancers) (PMC8081906).

2. Etiology

Disease Causal Factors

LCNEC does not have a single monogenic cause; it is a somatically acquired, multi-hit malignancy arising in transformed pulmonary neuroendocrine cells or a common progenitor shared with non-neuroendocrine lung epithelium, driven predominantly by tobacco-carcinogen-induced mutagenesis culminating in near-universal biallelic TP53 inactivation plus a second driver event (RB1 or STK11/KEAP1) (George et al., Nat Commun 2018, PMID:29535388). A minority of LCNECs arise via histologic transformation from EGFR-mutant lung adenocarcinoma under the selective pressure of EGFR-tyrosine-kinase-inhibitor therapy, driven mechanistically by biallelic RB1 loss (search synthesis of transdifferentiation literature; PNAS 2019 mouse-model paper, https://www.pnas.org/doi/10.1073/pnas.1821745116).

Risk Factors

Genetic/molecular risk factors (somatic, tumor-intrinsic; germline predisposition is not well established for sporadic LCNEC): - Biallelic TP53 inactivation — present in 64–92% of cases across cohorts (synthesis of PMID:33968782 review data). - Biallelic RB1 inactivation — 19–42% (concurrent with TP53 in "Type II/SCLC-like" tumors). - STK11/KEAP1 alterations — 17–33% (concurrent with TP53 in "Type I/NSCLC-like" tumors). - KRAS mutations — 4–24%. - NOTCH family gene alterations (inactivating) — 10–16%, implicated in loss of neuroendocrine differentiation control (George et al., PMID:29535388). - MYC family amplification (particularly MYCL, MYCN, MYC) has been implicated in driving transitions between neuroendocrine lineage states (ASCL1→NEUROD1 transition) that phenocopy LCNEC-like histology in SCLC models (Sci Adv 2020, https://www.science.org/doi/10.1126/sciadv.abc2578).

Environmental/behavioral risk factors: - Tobacco smoking is overwhelmingly the dominant risk factor: 92.8–98% of LCNEC patients have a smoking history, with many series reporting >40 pack-years in a majority of patients (PMC8162139; PMC9428409; PMC6532618). This mutagenic burden underlies the very high tumor mutational burden and TP53/STK11/KEAP1/KRAS mutation spectrum shared with squamous cell lung carcinoma and SCLC. - Age: median age at diagnosis ~65–66 years, skewing toward older adults (PMC8081906; PMID:33968782). - Sex: strong male predominance, consistent with the historical smoking-exposure skew, though the male:female gap has been narrowing in more recent cohorts as female smoking rates changed. - Prior EGFR-TKI exposure in EGFR-mutant adenocarcinoma is a specific, mechanistically defined risk pathway for acquired (transformed) LCNEC/SCLC.

Protective Factors

No established genetic or environmental protective factors specific to LCNEC have been robustly identified in the literature reviewed; smoking cessation reduces overall lung cancer risk generically but LCNEC-specific protective/modifier data are sparse.

Gene–Environment Interactions

The dominant gene–environment interaction is the tobacco-carcinogen mutational signature (SBS4-type, characterized by G>T transversions) converging on the TP53/RB1/STK11/KEAP1 tumor-suppressor network — i.e., chronic carcinogen exposure selects for and produces the specific biallelic tumor-suppressor loss-of-function events that define both LCNEC molecular subtypes. This is inferred from the near-universal smoking history combined with the mutational spectrum reported in comprehensive genomic profiling studies (George et al. PMID:29535388; Rekhtman et al., Clin Cancer Res 2016, "Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung," https://aacrjournals.org/clincancerres/article/23/3/757/80338).

3. Phenotypes

Clinical signs/symptoms (respiratory, driven by anatomic location)

Centrally located tumors (a substantial minority, more than typical NSCLC adenocarcinoma but less central than SCLC): cough, hemoptysis, bronchial obstruction, post-obstructive/recurrent pneumonia.
Suggested HPO terms: Cough (HP:0012735), Hemoptysis (HP:0002105), Recurrent respiratory infections (HP:0002205).
Peripherally located tumors: frequently asymptomatic, identified incidentally on imaging — reflecting the tendency of LCNEC to present as a peripheral nodule/mass more often than SCLC.
Constitutional/systemic symptoms at presentation in advanced disease: weight loss, fatigue, dyspnea, chest pain.
HPO: Weight loss (HP:0001824), Fatigue (HP:0012378), Dyspnea (HP:0002094), Chest pain (not a canonical HPO term but codeable via SNOMED CT).

Paraneoplastic phenomena

LCNEC, sharing biology with SCLC, can produce paraneoplastic syndromes, though less commonly reported than in classic SCLC: - SIADH/hyponatremia (inappropriate ADH secretion) - Cushing syndrome (ectopic ACTH) - Lambert–Eaton myasthenic syndrome - Paraneoplastic neurological syndromes — peripheral neuropathy, limbic encephalitis, and case reports of opsoclonus-myoclonus syndrome as the presenting feature preceding LCNEC diagnosis (PMC10725307; AJRCCM abstract 2025). - Rare carcinoid-syndrome-like flushing/diarrhea has been described but is atypical for high-grade NEC. - Suggested HPO terms: Hyponatremia (HP:0002902), Cushingoid facies (HP:0000174), Myasthenia (HP:0003473), Peripheral neuropathy (HP:0009830), Encephalitis (HP:0002383).

Laboratory abnormalities

Elevated serum neuron-specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP) may be seen (SCLC-associated markers, less validated specifically for LCNEC).
Chromogranin A elevation in serum can occur but is neither sensitive nor specific.

Phenotype characteristics

Age of onset: predominantly adult/older-adult onset (median 65–66 years); pediatric/young-adult LCNEC is exceptionally rare (case reports exist, e.g., tarlatamab case report in a young adult, JTO Clin Res Rep).
Severity: uniformly high grade/aggressive by definition (WHO diagnostic criterion requires high mitotic count and often necrosis).
Progression: rapidly progressive; a majority of patients present with locoregionally advanced or metastatic (stage IV) disease — one large cohort reported 54.6% presenting at stage IV (synthesis, PMID:33968782).
Frequency among affected individuals: By definition, the histologic/molecular features described (necrosis, high Ki-67, TP53 alteration) are present in nearly all diagnosed cases since they constitute diagnostic criteria; paraneoplastic phenomena are comparatively uncommon (case-report level).

Quality of life impact

Given the aggressive course, poor prognosis (median OS 8–12 months in advanced disease; see Section 11), and frequent late-stage diagnosis, quality-of-life burden is substantial — encompassing respiratory symptom burden, treatment-related toxicity from platinum-etoposide chemotherapy or immunotherapy-related adverse events, and, in a subset, paraneoplastic neurological morbidity that can itself be disabling (e.g., the opsoclonus-myoclonus case series notes significant residual gait instability). Disease-specific QoL instrument data (e.g., EORTC QLQ-LC13) specific to LCNEC (as opposed to lung cancer broadly) were not identified in this search.

4. Genetic/Molecular Information

Causal/driver genes and prevalence (from integrative genomic cohorts)

Table (click to expand)

Gene	Alteration type	Prevalence (pooled from Rekhtman 2016, George et al. 2018 [PMID:29535388], and subsequent reviews)
TP53 (HGNC:11998)	Biallelic loss-of-function (missense, truncating, LOH)	64–92%
RB1 (HGNC:9884)	Biallelic inactivation	19–42%
STK11 (HGNC:11389)	Inactivating mutation	17–33%
KEAP1 (HGNC:6396)	Inactivating mutation	19–31%
KRAS (HGNC:6407)	Activating mutation (mutually near-exclusive w/ RB1 loss)	4–24%
NOTCH1/2/3/4 family	Inactivating mutations	10–16%
MYC/MYCL/MYCN	Amplification	Reported in subsets, associated with lineage-state transitions

Molecular subtyping — Type I vs. Type II LCNEC

The landmark integrative genomic/transcriptomic study by George et al. (Nat Commun 2018, n=75 LCNEC, genomic n=60, transcriptomic n=69; PMID:29535388) defined two largely mutually exclusive molecular subgroups:

Type I LCNEC ("NSCLC-like"): biallelic TP53 + STK11/KEAP1 co-alteration (~37% of the discovery cohort, with other cohorts reporting 13–40%). Transcriptionally these tumors resemble SCLC/carcinoid neuroendocrine programs: ASCL1^high / DLL3^high / NOTCH^low.
Type II LCNEC ("SCLC-like"): biallelic TP53 + RB1 co-alteration (~35–42% of cohorts). These tumors show reduced neuroendocrine differentiation relative to SCLC, with a pattern of ASCL1^low / DLL3^low / NOTCH^high, and notably an upregulation of immune-related pathways — a potential biological basis for differential immunotherapy responsiveness.
Despite sharing individual genomic alterations with lung adenocarcinoma and squamous cell carcinoma, LCNEC forms its own distinct transcriptional cluster most similar to SCLC, not to NSCLC histologic subtypes — supporting the WHO reclassification of LCNEC as a neuroendocrine carcinoma rather than an NSCLC variant.
Follow-up real-world cohort data (PMID:33968782-linked synthesis) found substantial heterogeneity: in some series 52.7% of cases do not cleanly classify as either Type I or Type II, underscoring that this is a useful but imperfect binary framework, likely reflecting a spectrum/continuum of neuroendocrine differentiation states rather than two discrete classes.

Transcription-factor-based (SCLC-style) subtyping applied to LCNEC

Building on the four-subtype SCLC transcriptional classification (ASCL1, NEUROD1, POU2F3, YAP1), recent work has extended this framework to LCNEC: - A 2025 Nature Communications integrated molecular/clinical characterization of pulmonary LCNEC (https://www.nature.com/articles/s41467-025-63091-0) and companion analyses of NEUROD1/ASCL1/POU2F3/YAP1 expression signatures found that ~80% of LCNEC transcriptomes align with an SCLC-like transcriptional profile, predominantly ASCL1-driven or NEUROD1-driven with a smaller YAP1-high, low-neuroendocrine subgroup. - Prognostic implication: NE-high subtypes (especially NEUROD1-dominant) show the worst overall survival, whereas the YAP1-high subgroup — characterized by low neuroendocrine differentiation, elevated immune infiltration, and higher Rb protein expression — is associated with relatively better prognosis and potentially greater immunotherapy sensitivity. A cross-tissue five-transcription-factor classification framework for neuroendocrine carcinomas generally (Cancer Cell 2024, https://www.cell.com/cancer-cell/fulltext/S1535-6108(24)00163-6) situates LCNEC within this broader neuroendocrine-carcinoma taxonomy.

Variant classification and population frequency

Most driver alterations in LCNEC are somatic, not germline; population allele-frequency databases (gnomAD, ExAC) are not directly informative for a somatic-driver cancer, though tumor-suppressor loss-of-function variant classes (nonsense, frameshift, canonical splice-site, large deletion/LOH) predominate for TP53/RB1/STK11/KEAP1, consistent with a classical two-hit tumor-suppressor mechanism.

Functional consequences

TP53 loss-of-function abrogates DNA-damage checkpoint control and apoptosis, permitting genomic instability.
RB1 biallelic loss removes the G1/S checkpoint brake, permitting unrestrained proliferation and correlating with a more SCLC-like, highly proliferative, RB1-null, low-differentiation phenotype (consistent with dismech's general RB1/CDK4-6/E2F "evading growth suppressors" pattern).
STK11 (LKB1) loss deregulates AMPK/mTOR energy-sensing signaling and is separately associated (in NSCLC broadly) with impaired response to immune checkpoint blockade, a clinically important correlate carried into LCNEC Type I tumors.
KEAP1 loss constitutively activates NRF2 antioxidant signaling, promoting chemoresistance.

Chromosomal/epigenetic information

Comprehensive DNA methylation or chromatin-state datasets specific to LCNEC were not prominently returned in this search; the transcription-factor-driven lineage-state model (ASCL1/NEUROD1/POU2F3/YAP1) is understood to be substantially governed by chromatin-level lineage plasticity analogous to SCLC, but LCNEC-specific epigenomic (ENCODE/Roadmap-style) datasets are not yet a major established resource for this tumor type — noted here as a data gap.

5. Environmental Information

Tobacco smoke (the dominant environmental exposure) — see Section 2. Suggested exposure term: ECTO tobacco-smoke-exposure class terms (e.g., analogous to "exposure to cigarette smoke").
No specific occupational toxin, radiation, or pollution exposure was identified in the literature reviewed as an independent LCNEC risk factor beyond the generic lung-carcinogen literature (radon, asbestos) that applies to lung cancer broadly; LCNEC-specific epidemiologic case-control data isolating these factors were not found in this search.
Infectious agents: no established infectious/microbial etiology for pulmonary LCNEC. (Extrapulmonary neuroendocrine carcinomas at some sites, e.g., cervix, may co-occur with high-risk HPV infection as a contributing oncogenic driver at that anatomic site, analogous to the mechanism captured in the viral_oncogenesis module for HPV-driven cervical carcinoma, but this is a site-specific consideration for cervical LCNEC rather than a general LCNEC etiology.)

6. Mechanism / Pathophysiology

Cell of origin

LCNEC is believed to arise from pulmonary neuroendocrine cells (PNECs) or a shared basal/neuroendocrine progenitor, analogous to SCLC. Supporting evidence: expression of the master neuroendocrine transcription factor ASCL1 (achaete-scute homolog 1), normally restricted to PNECs, is retained in the neuroendocrine-high subset of LCNEC and SCLC, "indicating the neuroendocrine cell origin of these malignancies" (search synthesis). Suggested Cell Ontology term: pulmonary neuroendocrine cell (CL:0002251).

Mouse genetic models directly demonstrate that cell-of-origin determines tumor phenotype given an identical genetic lesion set: combined inactivation of Rb1, Rbl1 (p130), Pten, and Trp53 ("quadruple knockout") in all lung epithelial cell types (via Ad5-CMV-Cre) produces LCNEC, whereas the identical genetic inactivation restricted to basal cells (via Ad5-K5-Cre) produces SCLC instead (Ferone et al., PNAS 2020, https://www.pnas.org/doi/10.1073/pnas.1821745116). This is strong mechanistic (model-organism) evidence that LCNEC and SCLC are genetically overlapping but cell-of-origin-divergent neuroendocrine carcinomas — a key causal-chain insight: identical driver mutations (Rb1/Trp53/Pten loss) + differing epithelial cell-of-origin context → divergent histologic/molecular tumor phenotype (LCNEC vs. SCLC).

Molecular pathway cascade (causal chain)

Chronic tobacco-carcinogen mutagenesis in bronchial/PNEC epithelium →
Biallelic TP53 inactivation (near-universal, "gatekeeper" first hit) →
Second-hit bifurcation into two convergent-but-distinct pathway states:
RB1 co-loss → loss of G1/S checkpoint restraint → E2F-driven hyperproliferation, high neuroendocrine differentiation program suppression (ASCL1^low/DLL3^low), NOTCH pathway de-repression (NOTCH^high) → "Type II/SCLC-like" phenotype with high Ki-67 and immune-pathway upregulation.
STK11/KEAP1 co-loss → AMPK/mTOR and NRF2 pathway dysregulation, retained ASCL1^high/DLL3^high neuroendocrine program, NOTCH^low → "Type I/NSCLC-like" phenotype.
Downstream: loss of NOTCH-mediated lateral inhibition permits expansion of the neuroendocrine lineage program (paralleling the conserved Notch-controlled neuroendocrine-vs-non-neuroendocrine fate switch described generally for high-grade lung NECs).
MYC-family (MYC/MYCL/MYCN) amplification can further drive lineage-state transitions (e.g., ASCL1-dominant → NEUROD1-dominant transcriptional states), which histologically and biologically manifest with LCNEC-like features even within an SCLC genomic background (Sci Adv 2020).
Net result: unrestrained proliferation (high Ki-67, mean ~65.8%±20.8%), geographic tumor necrosis, and a highly aggressive, chemotherapy-initially-responsive but rapidly relapsing clinical phenotype.

Molecular functions / biological processes (suggested GO terms)

Negative regulation of cell cycle G1/S transition (RB1 loss → GO:0000082 positive regulation of G1/S transition, dysregulated)
DNA damage response / apoptotic signaling (TP53; GO:0006977, GO:0006915)
Notch signaling pathway (GO:0007219)
Regulation of neuroendocrine cell differentiation (GO:0071679-adjacent / achaete-scute lineage specification)
Cellular response to oxidative stress via NRF2/KEAP1 (GO:0034614, GO:1901031 — regulation of response to oxidative stress)
AMPK/mTOR signal transduction via STK11/LKB1 (GO:0032008 relevant analog)

Immune microenvironment

Type II (RB1-mutant) LCNEC shows upregulation of immune-related pathways transcriptionally, potentially correlating with the somewhat better observed responsiveness of RB1-altered/SCLC-like LCNEC to immune checkpoint blockade in some series, while STK11/KEAP1-altered (Type I) tumors — mirroring the well-established NSCLC finding — appear associated with poorer immunotherapy response (search synthesis of PMID:33968782-linked review).

Molecular profiling technologies applied

Transcriptomics: RNA-seq-based lineage subtyping (ASCL1/NEUROD1/POU2F3/YAP1) — see Section 4.
Genomics: targeted and whole-exome sequencing cohorts (George et al. PMID:29535388; Rekhtman et al. 2016).
Single-cell/spatial: not prominently represented in the literature surfaced by this search — a likely emerging area but not yet a mature LCNEC-specific resource base (data gap).
Functional genomics (CRISPR/DepMap): LCNEC-derived cell lines are represented within DepMap broadly as part of the neuroendocrine lung cancer cell line panel, but LCNEC-specific CRISPR screen publications were not surfaced in this search.

7. Anatomical Structures Affected

Organ level

Primary organ: lung (bronchus/lung parenchyma) is the prototypical and most-studied site — Uberon: lung (UBERON:0002048), bronchus (UBERON:0002185).
Extrapulmonary primary sites (each representing a distinct clinical entity under the same histologic/molecular umbrella): gastroenteropancreatic tract (esophagus, stomach, colon, rectum, pancreas), gynecologic tract (cervix, uterus/endometrium, ovary), genitourinary tract (bladder, prostate), breast, thymus, larynx/pharynx, paranasal sinus, and skin/other rare sites. Approximately 37% of extrapulmonary NECs occur in the gastroenteropancreatic tract, with the genitourinary and gynecologic tracts also well represented (PMC10743506).
Secondary/metastatic involvement: lung (contralateral/intrapulmonary), liver, bone, brain, and adrenal gland are common metastatic sites, mirroring SCLC's metastatic tropism. SEER-based analysis found single-organ metastasis in 26.0% and multi-organ metastasis in 14.8% of a cohort of 1,335 LCNEC patients, with lung and brain metastases each carrying a median OS of only 8 months (PMC8971719; PMC9773085).

Tissue/cell level

Neoplastic cell population: large epithelial cells with neuroendocrine morphology, derived from (or recapitulating) pulmonary neuroendocrine cells — CL:0002251 (pulmonary neuroendocrine cell) as the presumptive normal-cell analog.
Tumor architecture: organoid nesting, trabeculae, rosettes, palisading, with geographic necrosis.

Subcellular level

Neuroendocrine secretory-granule machinery is retained in tumor cells (basis for chromogranin A positivity, a dense-core-granule marker) — relevant GO Cellular Component: secretory granule (GO:0030141), specifically dense core granule (GO:0031045).

Localization

Approximately central vs. peripheral distribution is roughly split, with central tumors more often symptomatic (cough, hemoptysis, obstruction) and peripheral tumors more often incidental. No strong left/right or lobar lateralization pattern was identified in this search.

8. Temporal Development

Onset: adult-onset, typically 6th–7th decade of life (median ~65–66 years); pediatric and young-adult cases are rare outliers.
Onset pattern: often insidious for peripheral tumors (incidental imaging finding); can be more acute/subacute for centrally obstructing tumors (recurrent pneumonia, hemoptysis) or in cases presenting via paraneoplastic neurologic syndrome.
Staging: uses the standard AJCC/UICC TNM lung cancer staging system (same schema as NSCLC), unlike SCLC which is often staged with the older limited/extensive-stage system alongside TNM. A majority of patients (>50% in several cohorts) present at stage IV.
Progression rate: rapid; LCNEC's proliferative index (mean Ki-67 ~65.8%) situates it biologically between typical/atypical carcinoid (low-grade) and SCLC (very high-grade), but clinically it behaves aggressively, similar to SCLC.
Disease course pattern: generally progressive/relapsing rather than static; initial chemotherapy responses are often followed by relatively rapid relapse, paralleling the SCLC natural history.
Recurrence: common even after complete surgical resection in early-stage disease, motivating investigation of adjuvant chemotherapy (see Section 12).

9. Inheritance and Population

Epidemiology

Incidence: age-adjusted incidence of ~0.3 per 100,000 (0.4/100,000 in men, 0.3/100,000 in women), based on SEER 2000–2013 data; incidence appears to have been rising over time (from ~0.26 to 0.39 per 100,000 between 2004–2015 in one synthesis) — plausibly reflecting improved diagnostic recognition following the WHO reclassification as much as a true increase (PMC6441320; PMID:33968782-linked synthesis).
Proportion of lung cancers: LCNEC constitutes roughly 1–3% of all lung cancers, and pulmonary LCNEC accounts for 0.58% of all lung/bronchus carcinomas in one SEER-based accounting; it represents about 15% of all pulmonary neuroendocrine neoplasms.

Inheritance

LCNEC is predominantly a sporadic, somatically driven malignancy without an established Mendelian inheritance pattern (no OMIM entry for a monogenic LCNEC syndrome was identified). It is not classically associated with MEN1 or other hereditary neuroendocrine tumor syndromes the way well-differentiated NETs sometimes are, though the literature reviewed here did not surface data specifically excluding rare hereditary contributions in unusual young-onset cases.

Population demographics

Sex ratio: strong male predominance historically, tracking smoking-exposure demographics.
Age distribution: peaks in the 6th–7th decades; rare before age 40.
Geographic/ethnic variation: East Asian cohorts have been separately characterized genomically (Kang et al., PMID:33144445, "Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients"), suggesting some population-level genomic profiling differences exist, though a detailed comparative incidence/ethnicity breakdown was not fully resolved in this search.

10. Diagnostics

Histopathology and immunohistochemistry (the diagnostic cornerstone)

Diagnosis requires combined morphologic assessment plus immunohistochemical confirmation of neuroendocrine differentiation: - Neuroendocrine markers: chromogranin A (CgA), synaptophysin (Syn), and CD56/NCAM are typically diffusely positive; INSM1 and ASCL1 (hASH1) are emerging, high-sensitivity markers particularly useful in crush-artifact-limited small biopsy specimens (PathologyOutlines; PMID:33968782 synthesis). - Ki-67 proliferation index: characteristically high, mean ~65.8% (±20.8%) in one series, and is a key discriminator from carcinoid tumors (which have low Ki-67), especially valuable on small biopsies where architecture is hard to assess (PMC11404992). Higher Ki-67 within LCNEC itself has additional prognostic value. - TTF-1: variably positive; TTF-1/c-MYC co-expression phenotypes have been proposed as a stratification tool relevant to DLL3-targeted treatment selection (PMC8132912). - WHO recommends that a definitive LCNEC diagnosis, given tissue heterogeneity, be made preferentially on surgical resection specimens rather than small biopsies when possible, given sampling limitations.

Laboratory tests / biomarkers

Serum NSE, ProGRP, chromogranin A (adjunctive, non-diagnostic).

Imaging

[18F]-FDG PET/CT: LCNEC exhibits high glucose turnover due to poor differentiation and elevated GLUT1 expression, making FDG-PET well suited to staging, particularly nodal (N) staging, and superior to conventional CT in several validated series (EJNMMI Research, PMC8298649).
Somatostatin receptor imaging (¹¹¹In-pentetreotide/Octreoscan, newer ⁶⁸Ga-DOTATATE PET): more established for well-differentiated NETs; utility in high-grade LCNEC (which often has lower/variable SSTR2 expression than low-grade NETs) is comparatively limited, though it may aid staging in select SSTR-avid cases.

Genetic/genomic testing

Comprehensive genomic profiling (CGP) panels (NGS-based) are increasingly used both for diagnostic clarification (distinguishing LCNEC from poorly differentiated NSCLC or SCLC when morphology/IHC is ambiguous) and to inform Type I/Type II molecular subclassification with treatment implications (Lung Cancer journal, "Real-World Comprehensive Genomic Profiling Data for Diagnostic Clarity in Pulmonary LCNEC," https://www.lungcancerjournal.info/article/S0169-5002(23)00992-3/fulltext).
No standardized single-gene or hereditary-panel germline test is indicated given the sporadic somatic etiology.

Differential diagnosis

Poorly differentiated NSCLC (adenocarcinoma/squamous) lacking neuroendocrine markers; SCLC (smaller cell size, higher nuclear:cytoplasmic ratio, nuclear molding, absent nucleoli — key morphologic discriminators); atypical carcinoid (lower Ki-67, less necrosis).

Screening

No dedicated LCNEC-specific screening program exists; patients are typically captured within general low-dose CT lung cancer screening programs for high-risk smokers, though LCNEC-specific screening-detection yield data were not identified in this search.

11. Outcome/Prognosis

Survival statistics (population-based, SEER 2000–2013 cohort)

5-year lung cancer-specific survival: 20.7–20.8%
5-year overall survival: 16.7–16.8%
3-year OS / cancer-specific survival: 22.8% / 26.5% (PMC6441320)
Median overall survival (all comers, mixed-stage): reported around 8–12 months in several syntheses; one large cohort reported median OS 9.7 months from diagnosis (PMID:33968782-linked synthesis).
Metastatic disease: median OS of only 8 months for patients with either lung-only or brain-only single-organ metastasis, with 1-year survival rates of 33% and 29% respectively (PMC8971719).

Treatment-outcome-stratified survival (advanced/metastatic disease)

Chemotherapy alone: median OS ~6.5 months.
Chemo-immunotherapy: median OS ~9.6 months (numerically longer, though not always statistically significant in smaller retrospective series) (ScienceDirect nationwide registry study).
First-line platinum doublet chemotherapy: median OS ~9.0 months.
Non-platinum chemotherapy: median OS ~4.0 months.
Immune checkpoint inhibitor-containing regimens (in one series): median OS as high as 26.4 months, though this likely reflects selection bias toward better-performance-status patients in retrospective cohorts rather than a robustly randomized-trial-confirmed effect size.

Prognostic factors

Stage at diagnosis (dominant driver of prognosis).
Molecular subtype: NEUROD1-dominant/high-neuroendocrine transcriptional subtype associated with worse OS; YAP1-high/low-neuroendocrine subtype associated with comparatively better prognosis (Nature Communications 2025 integrated characterization).
Ki-67 index: higher values associated with worse survival within the LCNEC category (PMC11404992).
Complete surgical resection in early-stage disease is associated with markedly better outcomes; complete resection rates of ~94% with 90-day postoperative mortality of ~7% have been reported in surgical series.
Adjuvant chemotherapy after complete resection, particularly with an SCLC-type regimen (platinum-etoposide) rather than an NSCLC-type regimen, is associated with improved survival in several retrospective series, though a randomized-trial-level evidence base is still lacking, and benefit appears more consistent in stage IIB than stage IIA disease (PMC7736707; Translational Cancer Research).

Complications

Brain metastasis is common and carries a particularly poor prognosis; other complications parallel those of aggressive lung malignancy generally (post-obstructive pneumonia, pleural effusion, superior vena cava syndrome in central tumors, paraneoplastic morbidity as above).

12. Treatment

First-line systemic therapy (advanced/metastatic disease)

Platinum–etoposide doublet chemotherapy has been the standard first-line regimen for metastatic LCNEC for over a decade, based on the phase II GFPC 0302 study, extrapolating the SCLC treatment paradigm given LCNEC's biological/clinical overlap with SCLC (synthesis from Frontiers Management of LCNEC, PMID:34513663). No significant OS difference has been found between platinum-etoposide and platinum-gemcitabine/taxane regimens in comparative retrospective analyses.
NCIT concept: Chemotherapy (NCIT:C15632); Pharmacotherapy (NCIT:C15986), with therapeutic_agent bound to cisplatin/carboplatin (platinum agents) and etoposide (CHEBI terms available for both).

Immunotherapy

Immune checkpoint inhibitors (anti-PD-1/PD-L1, alone or combined with chemotherapy) show promising activity, especially in Type II (RB1-altered, immune-pathway-upregulated) tumors.
DART (SWOG S1609) basket trial of combination nivolumab + ipilimumab (dual anti-PD-1/anti-CTLA-4 blockade) in the high-grade/non-pancreatic neuroendocrine carcinoma cohort reported an objective response rate of 44% in the high-grade neuroendocrine carcinoma subset specifically (vs. 0% ORR in low/intermediate-grade disease), and 25–26% ORR in the broader nonpancreatic/high-grade cohorts overall (Patel et al., PMID:31969335; companion high-grade NEN cohort report PMID:33882143). Dosing: ipilimumab 1 mg/kg IV every 6 weeks + nivolumab 240 mg IV every 2 weeks.
Ongoing prospective trials are testing atezolizumab + platinum/etoposide as first-line therapy specifically in advanced pulmonary LCNEC (NCT05470595), and pembrolizumab-based regimens in previously treated high-grade neuroendocrine carcinomas broadly.
STK11/KEAP1 co-mutated (Type I) tumors are, by analogy with the broader NSCLC literature, associated with relative immunotherapy resistance — a molecularly grounded rationale for future biomarker-stratified trial design.

Emerging/targeted therapy

DLL3-targeted therapy: DLL3 (Notch-ligand family) is expressed on the surface of a majority of SCLC cells and is also expressed in LCNEC (particularly the ASCL1^high/DLL3^high Type I subgroup), representing a tumor-restricted therapeutic target absent from normal tissue.
Rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, showed early promise in phase II but failed in phase III trials and was discontinued.
Tarlatamab, a DLL3×CD3 bispecific T-cell engager, achieved a 55% objective response rate and median PFS of 4.9 months in the phase 2 DeLLphi-301 trial (in SCLC); case reports document partial responses in LCNEC as well, including in a young-adult patient (JTO Clin Res Rep; PMC11986208). Cytokine release syndrome is a recognized, generally manageable toxicity.
NCIT/therapeutic-modality mapping: therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE does not apply here — tarlatamab and Rova-T fall under MONOCLONAL_ANTIBODY/bispecific-engager and antibody-drug-conjugate categories respectively (best captured as MONOCLONAL_ANTIBODY or OTHER pending a dedicated bispecific-T-cell-engager modality value).

Surgery

Surgical resection with curative intent is the treatment of choice for early-stage (resectable) LCNEC, given the tumor's biological ambiguity and the general principle that localized high-grade lung tumors benefit from resection when feasible (EJNMMI Research). NCIT: Surgical Procedure (NCIT:C15329).

Radiation

Radiotherapy is used in the definitive, adjuvant, and palliative settings, including for brain metastasis management (whole-brain RT or stereotactic radiosurgery, by analogy with SCLC brain-metastasis management, though LCNEC-specific prophylactic cranial irradiation data are not well established).

Combination/sequential strategies

Endostar (an anti-angiogenic agent) plus pembrolizumab combined with platinum-doublet chemotherapy has been reported in case-report form as a novel first-line approach for advanced pulmonary LCNEC (PMC9202532).
Cabozantinib + nivolumab + ipilimumab is under investigation for poorly differentiated neuroendocrine tumors broadly (NCT04079712).

Treatment for extrapulmonary LCNEC

Platinum-based chemotherapy (mirroring SCLC/pulmonary LCNEC management) remains the standard-of-care backbone for extrapulmonary neuroendocrine carcinomas of any primary site, with further site-specific and biomarker-driven approaches under active investigation (PMC10743506).

13. Prevention

No LCNEC-specific primary, secondary, or tertiary prevention program was identified in the literature reviewed. Given the overwhelming (92–98%) association with tobacco smoking, primary prevention via smoking cessation and tobacco control is the principal actionable prevention lever, consistent with lung cancer prevention broadly (CDC/WHO tobacco control frameworks). Secondary prevention (early detection) relies on inclusion within standard low-dose CT lung cancer screening programs for eligible high-risk smokers, though LCNEC-specific screening sensitivity/yield data were not found. No LCNEC-specific vaccine, chemoprophylaxis, or genetic/carrier screening program exists, consistent with its sporadic somatic (non-hereditary) etiology.

14. Other Species / Natural Disease

Naturally occurring LCNEC as a distinct veterinary clinical entity is not well documented in the literature surfaced by this search; pulmonary neuroendocrine tumors are reported in veterinary oncology literature more generally, but a dedicated OMIA (Online Mendelian Inheritance in Animals) entry or veterinary case-series literature specific to "large cell neuroendocrine carcinoma" was not identified — noted here as a data gap rather than a confirmed absence.

15. Model Organisms

Genetically engineered mouse models (GEMMs)

The most directly relevant and well-characterized model system is the quadruple-knockout (QKO) mouse: conditional inactivation of Rb1, Rbl1 (p130), Pten, and Trp53 in lung epithelium. - Cre-driver-dependent phenotype divergence (Ferone et al., PNAS 2020, https://www.pnas.org/doi/10.1073/pnas.1821745116): - Ad5-CMV-Cre (targets all lung epithelial cell types) → large-cell neuroendocrine carcinoma. - Ad5-K5-Cre (targets basal cells specifically) → small-cell lung carcinoma. - This model directly demonstrates cell-of-origin as a determinant of neuroendocrine lung cancer histologic subtype given an identical combinatorial genetic lesion (Rb1/Rbl1/Pten/Trp53 loss), closely recapitulating the human TP53/RB1 co-mutation signature that defines "Type II/SCLC-like" LCNEC. - Phenotype recapitulation: the model produces "high-grade malignant neuroendocrine lung carcinomas strikingly similar to human disease," supporting high translational fidelity for the RB1/TP53-co-mutant molecular subtype specifically; it is less directly informative for the STK11/KEAP1-mutant ("Type I") molecular subtype, which would require a distinct genetic-lesion combination not centered on Rb1 loss. - Trp53 mutant-specific models: Trp53 point-mutant (rather than null) alleles have been shown to drive neuroendocrine lung cancer through a combination of loss-of-function and gain-of-function mechanisms, the latter specifically affecting chemotherapy response (Sotillo et al., Mol Cancer Ther 2017, PMID: available via https://pmc.ncbi.nlm.nih.gov/articles/PMC5716875/), offering a model for studying platinum-etoposide chemoresistance mechanisms.

Other model systems

Patient-derived cell lines/xenografts (PDX): referenced in genomic-profiling and DLL3/tarlatamab preclinical literature but not exhaustively catalogued in this search; LCNEC-specific cell lines exist within broader neuroendocrine lung cancer cell line resources (e.g., within DepMap/Cellosaurus), though a dedicated LCNEC PDX registry akin to CCLE/DepMap-style comprehensive catalogs was not surfaced.
EGFR-mutant transformation models: mouse and cell-line models of EGFR-TKI-resistant transdifferentiation from adenocarcinoma to SCLC/LCNEC, centered on Rb1 biallelic inactivation, are used to study the acquired-resistance mechanistic pathway (search synthesis referencing PNAS 2020 and related EGFR-transdifferentiation literature).

Applications and limitations

These GEMMs are principally used to study: (1) the causal sufficiency of the TP53/RB1/Pten tumor-suppressor combination for high-grade neuroendocrine lung carcinoma, (2) the cell-of-origin determinant of LCNEC-vs-SCLC histologic fate, and (3) chemotherapy-response mechanisms tied to specific Trp53 mutant alleles. A key limitation is that no widely used GEMM directly models the STK11/KEAP1-driven "Type I" molecular subtype of human LCNEC, representing a translational gap for roughly a third of human cases.

Summary of Key Ontology-Term Suggestions

Table (click to expand)

Domain	Suggested term(s)
Disease	MONDO (large cell neuroendocrine carcinoma, organ-specific children); ICD-O-3 8013/3
Causal genes	HGNC:11998 (TP53), HGNC:9884 (RB1), HGNC:11389 (STK11), HGNC:6396 (KEAP1), HGNC:6407 (KRAS)
Cell of origin	CL:0002251 (pulmonary neuroendocrine cell)
Anatomy	UBERON:0002048 (lung), UBERON:0002185 (bronchus)
Key phenotypes	HP:0012735 (Cough), HP:0002105 (Hemoptysis), HP:0002902 (Hyponatremia), HP:0000174 (Cushingoid facies), HP:0003473 (Myasthenia), HP:0002383 (Encephalitis), HP:0001824 (Weight loss)
Biological processes	GO:0007219 (Notch signaling pathway), GO:0006977 (DNA damage response, p53 mediator), GO:1901031 (regulation of response to oxidative stress)
Treatments	NCIT:C15632 (Chemotherapy), NCIT:C15986 (Pharmacotherapy), NCIT:C15329 (Surgical Procedure), NCIT:C15313 (Radiation Therapy)

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	35
Resolved	35
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	35
On topic	31
Off topic	0

All extracted references resolved successfully.